Newsfeeds
Breaking World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.

World Pharma News
  • AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
    AstraZenecaAstraZeneca has launched a programme aimed at tackling the burden of hypertension in Africa. Healthy Heart Africa is designed in consultation and collaboration with non-governmental and community based organisations, international organisations, health experts and governments to support local health systems by increasing awareness of the symptoms and risks of hypertension and offering education, screening, treatment and control.

  • Scientists find genetic variants influence a person's response to statins
    A large analysis of over 40,000 individuals on statin treatment has identified two new genetic variants which influence how 'bad' cholesterol levels respond to statin therapy. Statins are widely prescribed to patients and have been shown to lower bad cholesterol levels by up to 55%, making them a highly effective method of reducing risk of heart disease.

  • Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
    Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and F-star Alpha Ltd. have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102.

  • Adverse drug reactions in children following use of asthma medications
    In a new study based on EU adverse drug reaction reports, researchers at the University of Copenhagen and the University of Southern Denmark now document that children's use of asthma medications may result in serious adverse drug reactions. The risk of adverse drug reactions is not fully documented in the pre-marketing clinical trials.

  • AstraZeneca strengthens partnership with the University of Cambridge
    AstraZenecaAstraZeneca, together with its global biologics research and development arm, MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.

  • Clinical trial could change standard treatment for stroke
    A large international clinical trial has shed new light on the effectiveness of current hospital protocols for managing blood pressure in stroke patients. The two-part ENOS trial (Efficacy of Nitric Oxide in Stroke,) was carried out at The University of Nottingham in collaboration with 23 countries to try to solve two major conundrums faced by doctors when treating people who have suffered a stroke

  • Protecting us from our cells
    Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found.

  • Analgesics and anti-inflammatory drugs may have an impact on depression
    Ordinary over the counter painkillers and anti-inflammatory drugs purchased from pharmacies may also be effective in the treatment of people suffering of depression. This is shown by the largest ever meta-analysis that has just been published by a research group from Aarhus University in the journal JAMA Psychiatry.

  • Viagra protects the heart beyond the bedroom
    Viagra could be used as a safe treatment for heart disease, finds new research published in the open access journal BMC Medicine. The study reveals that long-term daily treatment of Viagra can provide protection for the heart at different stages of heart disease, with few side effects.

  • Roche delivers solid sales growth for the first nine months of 2014
    RocheGroup sales were 34.8 billion Swiss francs, 5% higher at constant exchange rates and stable in Swiss francs for the nine months ended 30 September 2014. A number of currencies remained weaker against the Swiss franc throughout the year, most notably the US dollar, as well as all Latin American currencies and the Japanese yen.